Deletions in the 5q region, where Egr1 and several other tumor suppressor genes are mapped, is often observed in therapy-related myeloid neoplasms (t-MN) [9], a subset of patients with primary myelodysplastic syndrome (MDS), and about 15% of patients with acute myeloid leukemia (AML) de novo [10]. Here, EGR1 is linked to myelodysplastic syndrome.